ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,34
-0,80%
Dow Jones
40 211,72
0,53%
DAX
18 500,84
-0,53%
Brent Oil
83,155
-1,41%
Bitcoin
63 724,29
-1,74%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
13/03/202314h33Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202323h19Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202314h00Business WireTeva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
08/03/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202322h00Business WireTeva to Present at the Barclays Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
03/03/202313h03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/202322h13Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/202322h11Business WireTeva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender OfferNYSE:TEVATeva Pharmaceutical Industries Ltd
27/02/202309h30Business WireTeva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/02/202309h30Business WireTeva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026NYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202314h00Business WireTeva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
23/02/202314h00Business WireTeva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ LivesNYSE:TEVATeva Pharmaceutical Industries Ltd
18/02/202300h03Dow Jones NewsTeva Gets FDA Approval for Movement Disorders TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
17/02/202322h56Business WireTeva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/202321h33Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NYSE:TEVATeva Pharmaceutical Industries Ltd
10/02/202313h04Edgar (US Regulatory)Annual Report (10-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202315h05Dow Jones NewsTeva to Pay Florida $6.7 Million to Settle Price-Fixing AllegationsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202314h00Business WireTeva Reaches Agreement With Florida to Settle the State’s Price Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/202322h23Edgar (US Regulatory)Securities Registration (ads, Immediate) (f-6ef)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/202313h00Business WireTeva Reports Fourth Quarter and Full Year 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
23/01/202315h35Dow Jones NewsTeva Seeks FDA OK for Generic Form of Catalyst's FirdapseNYSE:TEVATeva Pharmaceutical Industries Ltd
19/01/202313h00Business WireTeva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)NYSE:TEVATeva Pharmaceutical Industries Ltd
12/01/202322h30Business WireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
09/01/202315h13Dow Jones NewsTeva Moves Forward With Nationwide Opioid SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/01/202314h00Business WireTeva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/202320h21Dow Jones NewsAlvotech, Teva Shares Rise After FDA Accepts BLA for AVT04NYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/202313h00Business WireAlvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/01/202322h30Business WireTeva to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/202210h00GlobeNewswire Inc.Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
13/12/202219h24Dow Jones NewsVanda Pharmaceuticals Shares Tumble After Loss in Hetlioz Patent SuitNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

NASDAQ
GRALV
GRAIL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés